Journal of the European Academy of Dermatology and Venereology

New major survey presented at the EADV Congress finds 'healthy' suntan myths persist despite warnings about skin cancer and aging

Retrieved on: 
Thursday, September 8, 2022
People, Surge arrester, Awareness, Skin cancer, IPSOS, Journal of the European Academy of Dermatology and Venereology, Congress, Coffee, Cosmetics, Venereology, Dermatology

MILAN, Sept. 8, 2022 /PRNewswire/ -- This is despite decades of awareness campaigns linking too much sun exposure to skin cancer and ageing in many countries.

Key Points: 
  • MILAN, Sept. 8, 2022 /PRNewswire/ -- This is despite decades of awareness campaigns linking too much sun exposure to skin cancer and ageing in many countries.
  • Other myths included believing sun protection was not needed in cloudy weather and that you did not need sunscreen if you already had a tan.
  • "We must drive awareness of the damage to skin cells caused by exposure to the sun, which can lead to photoaging and skin cancer.
  • This is particularly important in Europe where sun protection appears most inadequate compared to other countries" added Prof. Thierry Passeron.

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

Retrieved on: 
Thursday, September 8, 2022
University, Dupilumab, Itch, Journal of the European Academy of Dermatology and Venereology, Skin, Union, Quality of life, Priority review, Atopic dermatitis, Congress, University of Miami, Prurigo nodularis, Review, Patient, Medical device, Pharmaceutical industry, Medical imaging, Venereology, Prurigo, Dermatology

These data from one of two pivotal trials in prurigo nodularis show Dupixent significantly reduced itch and skin lesions at 24 weeks.

Key Points: 
  • These data from one of two pivotal trials in prurigo nodularis show Dupixent significantly reduced itch and skin lesions at 24 weeks.
  • The late-breaking data presented at the EADV 2022 Congress are from the randomized, placebo-controlled Phase 3 PRIME trial, which met its primary and key secondary endpoints.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indication.
  • AEs most commonly observed with Dupixent (5%) included nasopharyngitis (5% Dupixent, 4% placebo) and headache (5% Dupixent, 5% placebo).

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Retrieved on: 
Thursday, September 8, 2022
Icahn School of Medicine at Mount Sinai, Safety, Therapy, Professor, Itch, Notalgia paresthetica, Week, Department, Mount Sinai, GLOBE, Journal of the European Academy of Dermatology and Venereology, Nasdaq, News, Congress, NP, Patient, Dentistry, Pharmaceutical industry, Venereology, Dermatology

STAMFORD, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP). The data will be presented today by Mark Lebwohl, M.D., the lead investigator and Professor and Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, during a late-breaking news session at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • A statistically significant reduction in itch intensity was observed with oral difelikefalin at Day 1 compared to placebo and the effect was maintained through Week 8.
  • At Week 8, a significantly greater proportion of patients receiving oral difelikefalin vs. placebo achieved a complete response (22% difelikefalin vs. 5% placebo, p
  • Oral difelikefalin was generally well tolerated, with all adverse events in difelikefalin-treated patients reported as mild or moderate in severity.
  • The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.

LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress

Retrieved on: 
Thursday, September 8, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, AES, Safety, Research, Atopic dermatitis, United Arab Emirates, Conjunctivitis, Itch, Science, Upper respiratory tract infection, Adult, Congress, Patient, American Academy of Dermatology, Hope, Canon AE-1, Headache, LEO, Respiratory tract, Eczema herpeticum, TCS, Cancer, Leo Pharma, Development, AAD, Disease, DKK, Annual general meeting, Skin, Journal of the European Academy of Dermatology and Venereology, American Academy, DDI, Efficacy, Drug, Union, Pharmaceutical industry, Vaccine, Fair, Tralokinumab, Venereology, Tralokinumab, Dermatology

LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for Adtralza (tralokinumab) for adult patients with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for Adtralza (tralokinumab) for adult patients with moderate-to-severe atopic dermatitis (AD).
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Tuesday, September 6, 2022
PDE4, NDA, Safety, Form 10-K, Dermatitis, Time, U.S. Securities and Exchange Commission, Risk, FAAD, LinkedIn, SEC, Psoriasis, GLOBE, Journal of the European Academy of Dermatology and Venereology, Nasdaq, Company, FDA, Atopic dermatitis, News, Twitter, CEST, 2021 Essex County Council election, Face, Congress, Plaque, Scalp, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Venereology, Facebook, Dermatology

Specifically, new data from the STRATUM Phase 3 pivotal trial of roflumilast foam in seborrheic dermatitis will be presented in a late-breaking news session.

Key Points: 
  • Specifically, new data from the STRATUM Phase 3 pivotal trial of roflumilast foam in seborrheic dermatitis will be presented in a late-breaking news session.
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.
  • ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
  • Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

Retrieved on: 
Monday, August 29, 2022
Ichthyosis, Security (finance), X-linked recessive inheritance, Safety, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Incidence, Lumber, CI, CONTROL, CMC, Isotretinoin, Quality of life, Chemistry, U.S. Securities and Exchange Commission, GLOBE, Journal of the European Academy of Dermatology and Venereology, Company, FDA, 2021 Essex County Council election, Genta (company), Congress, Private Securities Litigation Reform Act, Intellectual property, Industry, Annual report, Patient, Nature, Pharmaceutical industry, Dermatology

BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that seven abstracts detailing positive clinical data from the completed Phase 2b CONTROL study of TMB-001 were accepted for e-poster presentation at the 31st European Academy of Dermatology and Venerology (EADV) Congress, which will be held in Milan, Italy and virtually from September 7-10, 2022. TMB-001 is a topical isotretinoin formulation in development based on the Company’s patented IPEG™ delivery system for the treatment of moderate to severe forms of congenital ichthyosis (CI), a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. In May 2022, the FDA designated TMB-001 as a breakthrough therapy for the treatment of CI.

Key Points: 
  • In May 2022, the FDA designated TMB-001 as a breakthrough therapy for the treatment of CI.
  • The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles.
  • The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI) and other sclerotic skin diseases.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.

Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cream, People, Inflammatory bowel disease, Inflammation, Pain, Obesity, Research, Smoking, Regulation of tobacco by the U.S. Food and Drug Administration, Genetics, Swelling, Psoriasis Area and Severity Index, Nose, Calendar, Aryl hydrocarbon receptor, Psoriasis, Rash, Stinger, Common, Incidence, Risk, Itch, Irritation, Food, Body surface area, Skin, LinkedIn, Roivant Sciences, Dermatology Life Quality Index, Headache, Quality of life, Cell, Depression, Itchy, Journal of the European Academy of Dermatology and Venereology, Hypertension, FDA, Therapy, Atopic dermatitis, Pivotal, Weather, Efficiency, Diabetes, Congress, Gesellschaft mit beschränkter Haftung, Folliculitis, Marketing, Patient, Cosmetics, Pharmaceutical industry, Venereology, Dermatology

VTAMA cream is approved for mild, moderate and severe plaque psoriasis, with no label restrictions on duration of use or body surface area.

Key Points: 
  • VTAMA cream is approved for mild, moderate and severe plaque psoriasis, with no label restrictions on duration of use or body surface area.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.
  • The FDA approved VTAMA cream for the topical treatment of mild, moderate, and severe plaque psoriasis in May 2022.